Skip to main content
Delfa

← All trials/NCT07374328

TRED

RecruitingPhase 1, PHASE2

Triple Hypoglycemic Regimens In Patients With Newly Diagnosed Type 2 Diabetes Mellitus

Comparison Of Two Triple Hypoglycemic Regimens In Achieving Glycemic Control And Diabetes Remission In Hospitalized Patients With Newly Diagnosed Type 2 Diabetes Mellitus: A Multicenter, Randomized, Clinical Study

Asset

Semaglutide

GLP-1 agonist

Listed sites

1

Recruiting sites

1

Estimated enrollment

240

Study population

Type 2 diabetes

Eligibility highlights

•HbA1c ≥9%

Primary endpoint

•Diabetes remission rate

Registered trial locations

Locations reported to ClinicalTrials.gov for this trial snapshot. Site count is not enrollment count; per-site enrollment is not available from source.

Identifiers

Registered as

NCT IDNCT07374328
Org study IDTRED

Timeline

Milestones

Study start2025-06-01actual
Study first posted2026-01-28actual
Last update posted2026-01-28actual
Primary completion2026-05-31estimated
Study completion2026-08-31estimated

Assets

Investigational agents

Semaglutide

Who this study enrolls

Type 2 diabetes

Who can enroll

Minimum age18 Years
Maximum age65 Years
SexAll
Healthy volunteersNot accepted

Inclusion criteria

•Patients with newly diagnosed type 2 diabetes.
•Age between 18 and 65 years old.
•HbA1c ≥ 9.0%.

Exclusion criteria

•Type 1 diabetes.
•Elevated creatinine or urinary albumin/creatinine.
•Combined with coronary heart disease, tumor or pregnancy.
•Receiving glucocorticoids.

Endpoints (4)

What's being measured

Protocol endpoints and posted registry outcome measures, grouped into outcome categories. Composite endpoints show their component event types. Standard codes (LOINC, SNOMED CT) are shown where available.

Coverage by outcome category

Glycemic / diabetes
2
Safety / tolerability / PK
2

Glycemic / diabetes

2 endpoints
Primary/protocol endpoint

Diabetes remission rate

Time frame:From enrollment to the end of follow-up at 11 months

threshold achievement, improvement

Secondary/protocol endpoint

HbA1c

Time frame:From enrollment to the end of follow-up at 11 months

descriptive, improvement

LOINC 4548-4

Safety / tolerability / PK

2 endpoints
Secondary/protocol endpoint

Hypoglycemia rate

Time frame:From enrollment to the end of follow-up at 11 months

event count, event

Secondary/protocol endpoint

Adverse reactions

Time frame:From enrollment to the end of follow-up at 11 months

Treatment-emergent AEs (any)

descriptive, event

Provenance

Sources

Trial identity, design, statusClinicalTrials.gov API v2
Snapshot dateJuly 6, 2026
Endpoint classificationDelfa endpoint taxonomy v2 (May 13, 2026)
Results tableno registry results posted yet

Trial facts come from public ClinicalTrials.gov records. Endpoint categories are Delfa's classification of those records, not a ClinicalTrials.gov field. All figures reflect the July 6, 2026 snapshot.